Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy

References

• Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis – update 2015. J Hepatol. 2015;62:S100–111.
   PubMed Web of Science ®Google Scholar
• Than NN, Oo YH. A concise review of autoimmune liver diseases. Autoimmunity – Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases. Available from: http://www.intechopen.com/books/autoimmunity-pathogenesis-clinical-aspects-and-therapy-of-specific-autoimmune-diseases/a-concise-review-of-autoimmune-liver-diseases.
   Google Scholar
• Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–497.
   PubMed Web of Science ®Google Scholar
• Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193–2213.
   PubMed Web of Science ®Google Scholar
• Werner M, Wallerstedt S, Lindgren S, et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol. 2010;45:457–467.
   PubMed Web of Science ®Google Scholar
• Vergani D, Mieli-Vergani G. Pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother. 2011;12:607–613.
   PubMed Web of Science ®Google Scholar
• Taubert R, Hardtke-Wolenski M, Noyan F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61:1106–1114.
   PubMed Web of Science ®Google Scholar
• Oo YH, Adams DH. Regulatory T cells and autoimmune hepatitis: what happens in the liver stays in the liver. J Hepatol. 2014;61:973–975.
   PubMed Web of Science ®Google Scholar
• Oo YH, Weston CJ, Lalor PF, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010;184:2886–2898.
   PubMed Web of Science ®Google Scholar
• Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int. 2010;4:475–493.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133:775–787.
   PubMed Web of Science ®Google Scholar
• Oo YH, Adams DH. Regulatory T cells and autoimmune hepatitis: defective cells or a hostile environment? J Hepatol. 2012;57:6–8.
   PubMed Web of Science ®Google Scholar
• Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology. 2013;145:521–536.
   PubMed Web of Science ®Google Scholar
• Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis. 2002;6:825–850, ix.
   PubMedGoogle Scholar
• Schramm C, Weiler-Normann C, Wiegard C, et al. Treatment response in patients with autoimmune hepatitis. Hepatology. 2010;52:2247–2248.
   PubMed Web of Science ®Google Scholar
• Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 1999;30:222–227.
   PubMed Web of Science ®Google Scholar
• Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063–3070.
   PubMed Web of Science ®Google Scholar
• Burak KW, Swain MG, Santodomingo-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27:273–280.
   PubMed Web of Science ®Google Scholar
• Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529–534.
   PubMed Web of Science ®Google Scholar
• Jothimani D, Cramp ME, Mitchell JD, et al. Treatment of autoimmune hepatitis: a review of current and evolving therapies. J Gastroenterol Hepatol. 2011;26:619–627.
   PubMed Web of Science ®Google Scholar
• Larsen FS, Vainer B, Eefsen M, et al. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13:3232–3236.
   PubMed Web of Science ®Google Scholar
• Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723–727.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Tamura K, Katayama N, et al. FK 506 assay past and present – characteristics of FK 506 ELISA. Transplant Proc. 1991;23:2725–2729.
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771–776.
   PubMed Web of Science ®Google Scholar
• Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.
   PubMed Web of Science ®Google Scholar
• Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepatitis. Lancet. 2013;382:1433–1444.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374–385.
   PubMed Web of Science ®Google Scholar
• Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology. 1987;7:1333–1339.
   PubMed Web of Science ®Google Scholar
• Schramm C, Lohse AW. Autoimmune hepatitis on the rise. J Hepatol. 2014;60:478–479.
   PubMed Web of Science ®Google Scholar
• Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371–375.
   PubMed Web of Science ®Google Scholar
• Oo YH, Neuberger J. Use of mycophenolate in the treatment of autoimmune hepatitis. Liver Int. 2005;25:687–691.
   PubMed Web of Science ®Google Scholar
• van Gerven NM, de Boer YS, Zwiers A, et al. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes Immun. 2015;16:247–252.
   PubMed Web of Science ®Google Scholar
• Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:405–407.
   PubMed Web of Science ®Google Scholar
• Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology. 2002;35:7–13.
   PubMed Web of Science ®Google Scholar
• Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805–809.
   PubMed Web of Science ®Google Scholar